Merck and Pfizer Underperform as Market Rally Widens the Pharma Divide

While U.S. equity markets prepared for a positive Tuesday, with S&P 500 and Nasdaq futures showing modest gains, two pharmaceutical heavyweights marched to a different drummer. Merck & Co. and Pfizer both underperform the broader market rally, with Merck’s stock retreating 1% and Pfizer sliding nearly 5%—a striking divergence that underscores shifting investor sentiment in the sector.

Why Pharma Giants Lag Behind Market Momentum

The underperformance came despite respectable earnings reports from both companies, even as technology and gold sectors continued their robust advance. The contrast highlights a critical question facing Big Pharma: while the broader economy accelerates, can traditional pharmaceutical players keep pace? Both Merck and Pfizer reported solid financials, yet the market punished them, suggesting investors are pricing in longer-term headwinds rather than celebrating short-term wins.

Merck’s Oncology Engine Drives Mixed Results

Merck reported a 5% surge in Q4 global sales reaching $16.4 billion, with full-year revenue exceeding $65 billion. The real story lies in oncology—the pillar of Merck’s business. Keytruda, its flagship cancer therapy, generated nearly $32 billion in annual sales, representing almost half the company’s total revenue and demonstrating a 7% year-over-year climb.

However, this dominance carries a ticking clock. As Keytruda faces eventual patent expiration later this decade, Merck has urgently ramped up its emerging portfolio. Winrevair, a hypertension medication, generated $1.4 billion in its debut year, while the pneumococcal vaccine Capvaxix contributed just under $800 million. The Animal Health division also impressed, with sales climbing 8% to $6.4 billion. For 2026, Merck projects revenue around $66 billion, signaling management’s confidence in near-term stability despite the looming Keytruda cliff.

Pfizer’s Pivot: Navigating Patent Cliffs and Pipeline Bets

Pfizer faced steeper challenges in 2025, with full-year revenue declining 2% to approximately $63 billion. Yet within this contraction lies a strategic reposition. The oncology segment held firm, bolstered by newer drugs like Padcev and Lorbrena, offsetting weakness elsewhere. Adjusted earnings per share climbed 4% to $3.22, driven by margin improvements and disciplined cost management.

Looking to 2026, Pfizer guided for revenue between $59.5 billion and $62.5 billion, with adjusted EPS between $2.80 and $3.00. The company openly acknowledges patent expiration headwinds and pricing pressures, but management remains confident that roughly 20 pivotal clinical studies launching this year will unlock future growth drivers. This is a company betting on its pipeline to rewrite its trajectory.

The Broader Picture: Pharma’s Moment of Transition

The underperformance of Merck and Pfizer reflects not weakness but transition. Both firms navigate patent cliffs with maturity and strategic foresight, quietly building next-generation portfolios while maintaining operational discipline. Their ability to deliver adjusted earnings growth and targeted revenue guidance—even as market multiples compress—demonstrates resilience in an industry facing structural change. For investors, the question isn’t whether these pharma titans will survive, but whether their emerging pipelines can reignite investor appetite before the old blockbusters fade.